Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase
inhibitors, mandate regular updating of concepts and management. A European …

In less than 10 years, the prognosis of chronic myeloid leukaemia has changed from that of
a fatal disease to a disorder amenable simply to lifelong oral medication and compatible …

Purpose We studied BCR-ABL1 transcript levels in patients with chronic myeloid leukemia in
chronic phase (CML-CP) at 3, 6, and 12 months after starting imatinib to identify molecular …

Few neoplastic diseases have undergone a transformation in a relatively short period like
chronic myeloid leukemia (CML) has in the last few years. In 1960, CML was the first cancer …

Although imatinib remains the gold standard for first-line treatment of chronic myeloid
leukemia (CML), increasing recognition of imatinib resistance and intolerance has led to the …

Early responses to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML)-
chronic phase (CP) are associated with improved outcome. We analyzed the impact of such …

The progress made in the understanding of chronic myeloid leukemia (CML) since the
recognition of a common chromosomal abnormality to the introduction of ever more effective …

Last year marked 30 years of hematopoietic stem cell transplantation as a curative treatment
of chronic myeloid leukemia (CML). Initially studies used stem cells from identical twins but …

Dasatinib is effective therapy for newly diagnosed patients with chronic myeloid leukemia,
but not all patients respond well. We analyzed the outcome of patients treated with dasatinib …

1St James's University Hospital, Leeds, 2Imperial College, London, 3University of
Southampton, Southampton, 4University Hospital, Nottingham, 5University Hospital of …